TICKERNERD
Menu
SPRBSPRBHealthcare · Biotechnology

SPRB Stock Forecast: Spruce Biosciences, Inc. Price Predictions for 2026-2027

Last close, 7 Aug 2026
$47

The 8 Wall Street analysts covering Spruce Biosciences, Inc. hold a median 12-month price target of $145 — +209.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 42 of 100 as at 8 Aug 2026 — in the lower half.

Market cap
$129.0M
Ticker Nerd rank
42 / 100
Median analyst target
$145
Analysts covering
8
Ticker Nerd rank

SPRB stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Spruce Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Aug 2026
42 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
83
Size
73
Momentum
69
Revisions
61
Volatility
51
Accruals
48
Value
25
Quality
19
Issuance
8

Growth (83): Sales and profits are climbing, and climbing faster than before.

Issuance (8): The company has been issuing shares or taking on financing, diluting existing holders.

The rank is the raw material. Whether the rules would actually own Spruce Biosciences, Inc. — and when they’d sell — is the membership.

Wall Street

SPRB stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SPRB, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says8 analysts
8 Buy0 Hold0 Sell
Low $120Median $145High $230

The green dot is the last close — the median target sits +209.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
13 July 2026B. Riley SecuritiesInitiatesBuy$160
16 June 2026GuggenheimInitiatesBuy—
9 June 2026Jones TradingInitiatesBuy—
1 June 2026HC Wainwright & Co.MaintainsBuy—
14 May 2026CitizensMaintainsMarket Outperform—
27 Apr 2026Craig-HallumInitiatesBuy—
10 Mar 2026CitizensMaintainsMarket Outperform—
10 Mar 2026HC Wainwright & Co.ReiteratesBuy—
19 Feb 2026HC Wainwright & Co.MaintainsBuy—
23 Dec 2025OppenheimerInitiatesOutperform—
22 Dec 2025HC Wainwright & Co.AssumesBuy$220
3 Dec 2025Leerink PartnersUpgradeOutperform—
11 Nov 2025CitizensMaintainsMarket Outperform—
28 Oct 2025JMP SecuritiesUpgradeMarket Outperform—
21 Oct 2025Leerink PartnersMaintainsMarket Perform—
16 Apr 2025RBC CapitalMaintainsSector Perform—
16 Dec 2024HC Wainwright & Co.ReiteratesNeutral—
12 Dec 2024GuggenheimReiteratesNeutral—
11 Dec 2024JMP SecuritiesDowngradeMarket Perform—
11 Dec 2024OppenheimerDowngradePerform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

SPRB analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
2
Fundamentals

Spruce Biosciences, Inc. (SPRB) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.9×

Cheaper than 82% of US stocks

Price / sales
—
Price / book
1.8×

Cheaper than 49% of US stocks

EV / EBITDA
−3.2×

Cheaper than 75% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 33% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−148.8%

Higher than 9% of US stocks

Return on assets
−37.2%

Higher than 11% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

SPRB vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
SPRBSpruce Biosciences, Inc.$129.0M
42
TLSATiziana Life Sciences Ltd. (Bermuda)$128.3M
20
HURATuHURA Biosciences, Inc.$129.3M
14
SEERSeer, Inc. (California)$122.1M
79
EQEquillium, Inc.$133.4M
29
INDPIndaptus Therapeutics, Inc.$133.6M
26
VANIVivani Medical, Inc.$119.4M
30
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SPRB appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest SPRB news & analysis

Spruce Biosciences Appoints Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development

Business Wire · 3 Aug 2026neutral

Spruce Biosciences, Inc. announced the appointment of Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development, effective the same day. Dr. Cohen Pfeffer brings more than a decade of biopharmaceutical industry experience to the role.

Why it matters — SPRB watchers would note the addition of an experienced clinical development leader to the management team as the company advances its late-stage neurological therapy programs.

Spruce Biosciences Appoints Adrian Quartel, M.D., FFPM, as Chief Medical Officer

Business Wire · 27 July 2026positive

Spruce Biosciences announced the appointment of Adrian Quartel, M.D., FFPM, as Chief Medical Officer, effective immediately. Dr. Quartel brings more than 25 years of experience in the international pharmaceutical industry.

Why it matters — A new Chief Medical Officer with over 25 years of pharmaceutical industry experience could influence the company's late-stage clinical development programs for neurological disorders.

FAQ

Frequently asked questions about SPRB stock

What is the SPRB stock price forecast for 2026-2027?

The 8 Wall Street analysts covering Spruce Biosciences, Inc. have a median 12-month price target of $145, with estimates ranging from $120 to $230. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SPRB stock a buy right now?

Of the 8 analysts covering Spruce Biosciences, Inc., 8 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Spruce Biosciences, Inc. 42 out of 100 across roughly 4,600 US stocks as at 8 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SPRB?

As at 8 Aug 2026, Spruce Biosciences, Inc. ranks 42 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (83 of 100).

Will SPRB stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +209.4% from the last close, and Ticker Nerd's factor model ranks Spruce Biosciences, Inc. 42 out of 100 as at 8 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SPRB stock forecast for 2030?

No analyst covering Spruce Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SPRB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $120 to $230 over the next 12 months.

What does Spruce Biosciences, Inc. do?

Spruce Biosciences Inc. is a late-stage biopharmaceutical company dedicated to developing and commercializing novel therapies for rare neurological and endocrine disorders with significant unmet medical needs.

What is the latest news on SPRB?

The most recent item we track (Business Wire, 3 Aug 2026): "Spruce Biosciences Appoints Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development". Spruce Biosciences, Inc. announced the appointment of Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development, effective the same day. Dr. Cohen Pfeffer brings more than a decade of biopharmaceutical industry experience to the role.

Company

About Spruce Biosciences, Inc.

Spruce Biosciences Inc. is a late-stage biopharmaceutical company dedicated to developing and commercializing novel therapies for rare neurological and endocrine disorders with significant unmet medical needs. Its lead program, tralesinidase alfa enzyme replacement therapy (TA-ERT), targets Sanfilippo Syndrome Type B (MPS IIIB), an ultra-rare, progressive, and fatal genetic disorder lacking FDA-approved treatments. Clinical data demonstrate TA-ERT's ability to profoundly reduce cerebral spinal fluid heparan sulfate non-reducing end (CSF HS-NRE), stabilize cognition, and preserve cortical grey matter volume, with the U.S. FDA granting Breakthrough Therapy Designation and confirming CSF HS-NRE as a surrogate biomarker. The company is advancing toward a biologics license application submission. Spruce Biosciences Inc. also pursues tildacerfont, a non-steroidal therapy for congenital adrenal hyperplasia aimed at enhancing disease control and reducing steroid dependency, alongside explorations in major depressive disorder and polycystic ovary syndrome through collaborations. Founded in 2014 and headquartered in South San Francisco, California, Spruce Biosciences Inc. operates in the rare disease space, emphasizing innovative treatments for patients with limited options.

CEO Dr. Javier Szwarcberg M.D., M.P.H. · 14 employees · United States · https://sprucebio.com